ImmunityBio: Q4 Earnings Snapshot

SelfRugger · 2026-03-02T07:46:20+00:00

ImmunityBio reported a Q4 loss of $61.9 million, or 6 cents per share, with $38.3 million in revenue. For the year, losses totaled $351.4 million on revenues of $113.3 million.

SelfRugger

2026-03-02 07:46:20

Abstract generation in progress

ImmunityBio: Q4 Earnings Snapshot

Associated Press Finance

Mon, February 23, 2026 at 11:40 PM GMT+9 1 min read

In this article:

IBRX

+22.95%

SAN DIEGO (AP) — SAN DIEGO (AP) — ImmunityBio, Inc. (IBRX) on Monday reported a loss of $61.9 million in its fourth quarter.

The San Diego-based company said it had a loss of 6 cents per share.

The immunotherapy company posted revenue of $38.3 million in the period.

For the year, the company reported a loss of $351.4 million, or 38 cents per share. Revenue was reported as $113.3 million.

This story was generated by Automated Insights () using data from Zacks Investment Research. Access a Zacks stock report on IBRX at

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.